GlassScriptPhysician profile
Manveen K Mann
NPI 1568967388
$1,170.04
in general payments reported to CMS, 2019-2025
16 companies · $618 in 2025
The $618 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.06 · 2022: $48.01 · 2023: $167 · 2024: $322 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $312.53 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $121.47 | 2024-2025 | Airsupra, Breztri |
| Dynavax Technologies Corporation | $106.30 | 2022-2024 | Heplisav-B |
| Abbvie INC. | $101.32 | 2024-2025 | |
| Exact Sciences Corporation | $93.65 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $92.84 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $76.53 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $52.32 | 2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $42.92 | 2024-2025 | Veozah |
| Abbott Laboratories | $41.28 | 2023-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $38.12 | 2025 | Inspire |
| Dexcom, INC. | $29.59 | 2023 | Dexcom G6 Transmitter |
| Ucb, INC. | $18.45 | 2024 | Fintepla |
| Glaxosmithkline, LLC. | $16.16 | 2024 | Arexvy, Shingrix |
| Amgen INC. | $14.05 | 2025 | Repatha, Otezla |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $12.51 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manveen Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.